OTLK logo

OTLK Outlook Therapeutics, Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$0.39
-0.01 (-2.74%)

Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for …

Market Cap: $94.94Mwww.outlooktherapeutics.com

Price

No data yet.

Social Signal Score

57
5d
—
30d
—
60d
60
2 mentions
—
90d
54
5 mentions
—
news: 5

Analyst Ratings

14 analysts
Buyconsensus
Strong Buy 0Buy 8Hold 6Sell 0Strong Sell 0
Avg price target$2.8+617.9%
Low $1.6Median $2.8High $4
Current Consensus

Revenue

$9.0K-98.18%
$-1.21M$1.15M$3.50M$5.85M
Sep 2016Jun 2026

Analyst Estimates

FY2025
$-1.80
$-1.93–$-1.65
4 analysts
FY2026
$-0.53
$-0.54–$-0.50
1 analysts
FY2027
$-0.20
$-0.31–$-0.07
3 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Robert Charles Jahr
Sector
Healthcare
Industry
Biotechnology
Employees
17
Beta
0.71
Country
US
Piotroski score
3 / 9 (Weak)
Altman Z-score
-41.54
www.outlooktherapeutics.com